

# Dawn L Hershman

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/1824209/dawn-l-hershman-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

376  
papers

12,592  
citations

56  
h-index

106  
g-index

408  
ext. papers

15,747  
ext. citations

4.5  
avg, IF

6.43  
L-index

#	Paper	IF	Citations
376	S1417CD: A Prospective Multicenter Cooperative Group-Led Study of Financial Hardship in Metastatic Colorectal Cancer Patients.. <i>Journal of the National Cancer Institute</i> , <b>2022</b> ,	9.7	4
375	Risk of Cardiometabolic Risk Factors in Women With and Without a History of Breast Cancer: The Pathways Heart Study.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , JCO2101738	2.2	2
374	Sex Differences in Risk of Severe Adverse Events in Patients Receiving Immunotherapy, Targeted Therapy, or Chemotherapy in Cancer Clinical Trials.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , JCO2102377	2.2	1
373	Abstract P4-11-16: Feasibility and patient satisfaction with a smartphone application to improve medication adherence among patients with breast cancer. <i>Cancer Research</i> , <b>2022</b> , 82, P4-11-16-P4-11-16 <sup>10.1</sup>		
372	Abstract P4-11-33: Continuous glucose monitoring and hyperglycemia during chemotherapy for early-stage breast cancer. <i>Cancer Research</i> , <b>2022</b> , 82, P4-11-33-P4-11-33	10.1	
371	Abstract PD8-07: Evaluation of Tucatinib + (Paclitaxel + Pertuzumab + Trastuzumab) followed by AC in high-risk HER2 positive (HER2+) stage II/III breast cancer: Results from the I-SPY 2 TRIAL. <i>Cancer Research</i> , <b>2022</b> , 82, PD8-07-PD8-07	10.1	
370	Abstract P3-02-04: Prediction of breast cancer response to neoadjuvant chemotherapy in different biological breast cancer subtypes using diffuse optical tomography. <i>Cancer Research</i> , <b>2022</b> , 82, P3-02-04-P3-02-04 <sup>10.1</sup>		
369	Abstract P4-11-04: A randomized adaptive sequential selection trial of cryotherapy, compression therapy, and placebo to prevent taxane induced peripheral neuropathy in patients with breast cancer. <i>Cancer Research</i> , <b>2022</b> , 82, P4-11-04-P4-11-04	10.1	
368	Risk of Cardiovascular Disease in Women With and Without Breast Cancer: The Pathways Heart Study.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , JCO2101736	2.2	4
367	Successes and challenges of implementing a cancer care delivery intervention in community oncology practices: lessons learned from SWOG S1415CD.. <i>BMC Health Services Research</i> , <b>2022</b> , 22, 432	2.9	0
366	The Breast Cancer Weight Loss trial (Alliance A011401): A description and evidence for the lifestyle intervention.. <i>Obesity</i> , <b>2022</b> , 30, 28-38	8	0
365	Use of Immune Checkpoint Inhibitor Pembrolizumab in the Treatment of High-Risk, Early-Stage Triple-Negative Breast Cancer: ASCO Guideline Rapid Recommendation Update.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , JCO2200503	2.2	0
364	Risk of heart failure with preserved versus reduced ejection fraction in women with breast cancer.. <i>Breast Cancer Research and Treatment</i> , <b>2022</b> , 193, 669	4.4	1
363	Effect of Metformin vs Placebo on Invasive Disease-Free Survival in Patients With Breast Cancer. <i>JAMA - Journal of the American Medical Association</i> , <b>2022</b> , 327, 1963	27.4	5
362	Association Between Health-Related Quality of Life and Progression-Free Survival in Patients With Advanced Cancer: A Secondary Analysis of SWOG Clinical Trials. <i>JCO Oncology Practice</i> , <b>2021</b> , OP2100407 <sup>2.3</sup>		1
361	Cognitive Functioning and Health in Hispanic/Latina Breast Cancer Survivors. <i>Journal of Immigrant and Minority Health</i> , <b>2021</b> , 1	2.2	0
360	Predictors of Pain Reduction in Trials of Interventions for Aromatase Inhibitor-Associated Musculoskeletal Symptoms.. <i>JNCI Cancer Spectrum</i> , <b>2021</b> , 5, pkab087	4.6	0

359	Total and out-of-pocket costs for PARP inhibitors among insured ovarian cancer patients. <i>Gynecologic Oncology</i> , <b>2021</b> , 160, 793-799	4.9	2
358	Persistent Disparity: Socioeconomic Deprivation and Cancer Outcomes in Patients Treated in Clinical Trials. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 1339-1348	2.2	12
357	Patient Knowledge and Expectations About Return of Genomic Results in a Biomarker-Driven Master Protocol Trial (SWOG S1400GEN). <i>JCO Oncology Practice</i> , <b>2021</b> , 17, e1821-e1829	2.3	1
356	Phase II study of propranolol feasibility with neoadjuvant chemotherapy in patients with newly diagnosed breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2021</b> , 188, 427-432	4.4	3
355	Patient factors associated with time to medication receipt of oral anti-cancer drugs.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 1519-1519	2.2	
354	Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 1485-1505	2.2	102
353	Inequity in location and quality of death of advanced cancer patients by immigrant status.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 12036-12036	2.2	
352	Use of fertility preservation services in male reproductive-aged cancer patients. <i>Gynecologic Oncology Reports</i> , <b>2021</b> , 36, 100716	1.3	0
351	Long-term results from a randomized blinded sham- and waitlist-controlled trial of acupuncture for joint symptoms related to aromatase inhibitors in early stage breast cancer (S1200).. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 12018-12018	2.2	0
350	Effect of metformin versus placebo on metabolic factors in the MA.32 randomized breast cancer trial. <i>Npj Breast Cancer</i> , <b>2021</b> , 7, 74	7.8	7
349	New and persistent controlled substance use among patients undergoing mastectomy and reconstructive surgery. <i>Breast Cancer Research and Treatment</i> , <b>2021</b> , 189, 445-454	4.4	0
348	Trends in ovarian conservation and association with survival in premenopausal patients with stage I leiomyosarcoma. <i>Gynecologic Oncology</i> , <b>2021</b> , 161, 734-740	4.9	0
347	Association of New Perioperative Benzodiazepine Use With Persistent Benzodiazepine Use. <i>JAMA Network Open</i> , <b>2021</b> , 4, e2112478	10.4	3
346	Challenges and opportunities to developing a frailty index using electronic health record data. <i>Journal of Geriatric Oncology</i> , <b>2021</b> , 12, 851-854	3.6	1
345	Phase I/II trial of ruxolitinib in combination with trastuzumab in metastatic HER2 positive breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2021</b> , 189, 177-185	4.4	2
344	Fragmentation of surgery and chemotherapy in the initial phase of ovarian cancer care and its association with overall survival. <i>Gynecologic Oncology</i> , <b>2021</b> , 162, 56-64	4.9	0
343	Diffuse optical tomography breast imaging measurements are modifiable with pre-surgical targeted and endocrine therapies among women with early stage breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2021</b> , 189, 297-304	4.4	0
342	Cancer Clinical Trial Participation at the 1-Year Anniversary of the Outbreak of the COVID-19 Pandemic. <i>JAMA Network Open</i> , <b>2021</b> , 4, e2118433	10.4	7

341	Physical Activity Before, During, and After Chemotherapy for High-Risk Breast Cancer: Relationships With Survival. <i>Journal of the National Cancer Institute</i> , <b>2021</b> , 113, 54-63	9.7	40
340	The Effect of Metformin vs Placebo on Sex Hormones in Canadian Cancer Trials Group MA.32. <i>Journal of the National Cancer Institute</i> , <b>2021</b> , 113, 192-198	9.7	10
339	"When Offered to Participate": A Systematic Review and Meta-Analysis of Patient Agreement to Participate in Cancer Clinical Trials. <i>Journal of the National Cancer Institute</i> , <b>2021</b> , 113, 244-257	9.7	30
338	Less radical surgery for early-stage cervical cancer: a systematic review. <i>American Journal of Obstetrics and Gynecology</i> , <b>2021</b> , 224, 348-358.e5	6.4	9
337	Cost of care for the initial management of cervical cancer in women with commercial insurance. <i>American Journal of Obstetrics and Gynecology</i> , <b>2021</b> , 224, 286.e1-286.e11	6.4	2
336	Opioid use and misuse in children, adolescents, and young adults with cancer: a systematic review of the literature. <i>Supportive Care in Cancer</i> , <b>2021</b> , 29, 4521-4527	3.9	0
335	Changes in Diffuse Optical Tomography Images During Early Stages of Neoadjuvant Chemotherapy Correlate with Tumor Response in Different Breast Cancer Subtypes. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 1949-1957	12.9	0
334	Patient-Reported Outcomes and Long-Term Nonadherence to Aromatase Inhibitors. <i>Journal of the National Cancer Institute</i> , <b>2021</b> , 113, 989-996	9.7	3
333	Association of Osteonecrosis of the Jaw With Zoledronic Acid Treatment for Bone Metastases in Patients With Cancer. <i>JAMA Oncology</i> , <b>2021</b> , 7, 246-254	13.4	11
332	Cancer Antigen 15-3/Mucin 1 Levels in CCTG MA.32: A Breast Cancer Randomized Trial of Metformin vs Placebo. <i>JNCI Cancer Spectrum</i> , <b>2021</b> , 5, pkab066	4.6	1
331	Care Delivery Impact of the COVID-19 Pandemic on Breast Cancer Care. <i>JCO Oncology Practice</i> , <b>2021</b> , 17, e1215-e1224	2.3	6
330	¡Mi Vida Saludable! A randomized, controlled, 2x2 factorial trial of a diet and physical activity intervention among Latina breast cancer survivors: Study design and methods. <i>Contemporary Clinical Trials</i> , <b>2021</b> , 110, 106524	2.3	4
329	Adolescent and young adult enrollment to a National Cancer Institute-sponsored National Clinical Trials Network Research Group over 25 years. <i>Cancer</i> , <b>2021</b> , 127, 4574-4584	6.4	1
328	In Reply. <i>Obstetrics and Gynecology</i> , <b>2021</b> , 138, 310-311	4.9	
327	Association of Fatigue and Outcomes in Advanced Cancer: An Analysis of Four SWOG Treatment Trials. <i>JCO Oncology Practice</i> , <b>2021</b> , 17, e1246-e1257	2.3	1
326	Adherence to PARP inhibitor therapy among women with ovarian cancer. <i>Gynecologic Oncology</i> , <b>2021</b> , 163, 262-268	4.9	1
325	Association Between Overall Survival and the Tendency for Cancer Programs to Administer Neoadjuvant Chemotherapy for Patients With Advanced Ovarian Cancer. <i>JAMA Oncology</i> , <b>2021</b> ,	13.4	3
324	Preference-weighted quality of life: Findings from the Selenium and Vitamin E Cancer Prevention Trial (SELECT).. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 144-144	2.2	

323	Integration of germline multigene panel testing into breast and gynecologic oncology clinics.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 164-164	2.2	
322	Incorporating systematic financial screening into the electronic health record.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 184-184	2.2	
321	Factors associated with failure to receive oral anticancer drugs.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 41-41	2.2	
320	Association between insurance plan, prior authorization, and time to receipt of oral anticancer drugs.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 6-6	2.2	1
319	Efficacy of a password-protected pill-dispensing device to enhance disposal of unused opioids after cancer surgery.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 264-264	2.2	
318	Impact of a hospital specialty pharmacy in partnership with a free-standing care coordination organization on time to delivery and receipt of oral anticancer drugs.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 43-43	2.2	
317	Effect of healthy diet and exercise on chemotherapy completion rate in women with breast cancer: The Lifestyle, Exercise and Nutrition Early after Diagnosis (LEANer) study: Study protocol for a randomized clinical trial. <i>Contemporary Clinical Trials</i> , <b>2021</b> , 109, 106508	2.3	2
316	Hospitalization burden and end-of-life (EOL) care in elderly patients with glioblastoma (GBM).. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 31-31	2.2	
315	Effects of neoadjuvant chemotherapy on the contralateral non-tumor-bearing breast assessed by diffuse optical tomography. <i>Breast Cancer Research</i> , <b>2021</b> , 23, 16	8.3	1
314	Trends in Human Papillomavirus Vaccination Among Women 27-45 years of age from 2017-2019.. <i>American Journal of Obstetrics and Gynecology</i> , <b>2021</b> ,	6.4	
313	Trends in Primary Treatment and Median Survival Among Women With Advanced-Stage Epithelial Ovarian Cancer in the US From 2004 to 2016. <i>JAMA Network Open</i> , <b>2020</b> , 3, e2017517	10.4	6
312	The effect of guideline-concordant care in mitigating insurance status disparities in cervical cancer. <i>Gynecologic Oncology</i> , <b>2020</b> , 159, 309-316	4.9	2
311	Randomized Trial of Text Messaging to Reduce Early Discontinuation of Adjuvant Aromatase Inhibitor Therapy in Women With Early-Stage Breast Cancer: SWOG S1105. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 2122-2129	2.2	26
310	Association of the Coronavirus Disease 2019 (COVID-19) Outbreak With Enrollment in Cancer Clinical Trials. <i>JAMA Network Open</i> , <b>2020</b> , 3, e2010651	10.4	51
309	Design, data linkage, and implementation considerations in the first cooperative group led study assessing financial outcomes in cancer patients and their informal caregivers. <i>Contemporary Clinical Trials</i> , <b>2020</b> , 95, 106037	2.3	1
308	Characteristics and outcomes of patients with breast cancer diagnosed with SARS-Cov-2 infection at an academic center in New York City. <i>Breast Cancer Research and Treatment</i> , <b>2020</b> , 182, 239-242	4.4	27
307	Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. <i>Lancet, The</i> , <b>2020</b> , 395, 1907-1918	10.4	880
306	Travel distance, hospital volume and their association with ovarian cancer short- and long-term outcomes. <i>Gynecologic Oncology</i> , <b>2020</b> , 158, 415-423	4.9	3

305	Cost-Effectiveness Analysis of Biomarker-Guided Treatment for Metastatic Gastric Cancer in the Second-Line Setting. <i>Journal of Oncology</i> , <b>2020</b> , 2020, 2198960	4.5	5
304	ASCO's Quality Care Symposium and the Evolving Science of Value-Based Care. <i>JCO Oncology Practice</i> , <b>2020</b> , 16, 113-114	2.3	0
303	Incidence and Predictors of Diabetes Mellitus after a Diagnosis of Early-Stage Breast Cancer in the Elderly Using Real-World Data. <i>Breast Cancer Research and Treatment</i> , <b>2020</b> , 183, 201-211	4.4	1
302	Association of Patient Demographic Characteristics and Insurance Status With Survival in Cancer Randomized Clinical Trials With Positive Findings. <i>JAMA Network Open</i> , <b>2020</b> , 3, e203842	10.4	17
301	A modern assessment of the surgical pathologic spread and nodal dissemination of endometrial cancer. <i>Gynecologic Oncology</i> , <b>2020</b> , 157, 329-334	4.9	1
300	Impact of quality of care on racial disparities in survival for endometrial cancer. <i>American Journal of Obstetrics and Gynecology</i> , <b>2020</b> , 223, 396.e1-396.e13	6.4	12
299	Guideline concordant care for prevention of acute chemotherapy-induced nausea and vomiting in children, adolescents, and young adults. <i>Supportive Care in Cancer</i> , <b>2020</b> , 28, 4761-4769	3.9	8
298	Oncology Practice During the COVID-19 Pandemic. <i>JAMA - Journal of the American Medical Association</i> , <b>2020</b> , 323, 2005-2006	27.4	144
297	Risk of cardiovascular disease in women with and without a history of breast cancer: The Pathways Heart Study.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 12016-12016	2.2	3
296	Predictive model of aromatase inhibitor non-adherence using patient-reported outcomes in women with breast cancer (SWOG S1105).. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 12019-12019	2.2	3
295	Cumulative incidence of financial hardship in metastatic colorectal cancer (mCRC) patients (pts): Primary endpoint results for SWOG S1417CD.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 137-137	2.2	1
294	A prospective study to validate the functional assessment of cancer therapy (FACT) for epidermal growth factor receptor inhibitor (EGFRI)-induced dermatologic toxicities FACT-EGFRI 18 questionnaire: SWOG S1013. <i>Journal of Patient-Reported Outcomes</i> , <b>2020</b> , 4, 54	2.6	0
293	Opioid prescribing practices in adolescent and young adults with sarcomas.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 136-136	2.2	
292	The association of patient fatigue and outcomes in advanced cancer: An analysis of four SWOG treatment trials.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 140-140	2.2	
291	The COVID-19 pandemic impact on breast cancer care delivery at an academic center in New York City.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 88-88	2.2	
290	When offered to participate—a systematic review and meta-analysis of patient agreement to participate in cancer clinical trials.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 92-92	2.2	1
289	Trends in obesity among patients registered to SWOG cancer clinical treatment trials.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 126-126	2.2	
288	Diagnosis of leptomeningeal metastasis (LM) through identification of circulating tumor cells (CTCs) in cerebrospinal fluid (CSF).. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 3567-3567	2.2	

287	Cumulative incidence of financial hardship in metastatic colorectal cancer patients: Primary endpoint results for SWOG S1417CD.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 7010-7010	2.2	6
286	Onset of cardiovascular disease risk factors in women with and without a history of breast cancer: The Pathways Heart Study.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 12017-12017	2.2	
285	Feasibility of a digital medicine program in optimizing opioid pain control in cancer patients (SWOG S1916).. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, TPS12126-TPS12126	2.2	
284	Beyond patient-level barriers: Evaluation of rural residency and area-level deprivation and clinical trial (CT) participation.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, e19068-e19068	2.2	
283	Phase III Randomized Trial of Bisphosphonates as Adjuvant Therapy in Breast Cancer: S0307. <i>Journal of the National Cancer Institute</i> , <b>2020</b> , 112, 698-707	9.7	22
282	Association between nonadherence to cardiovascular risk factor medications after breast cancer diagnosis and incidence of cardiac events. <i>Cancer</i> , <b>2020</b> , 126, 1541-1549	6.4	7
281	Dietary Supplement Use During Chemotherapy and Survival Outcomes of Patients With Breast Cancer Enrolled in a Cooperative Group Clinical Trial (SWOG S0221). <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 804-814	2.2	64
280	Prospective Study Evaluating Changes in Bone Quality in Premenopausal Women With Breast Cancer Undergoing Adjuvant Chemotherapy. <i>Clinical Breast Cancer</i> , <b>2020</b> , 20, e327-e333	3	4
279	Patterns of seizure prophylaxis after oncologic neurosurgery. <i>Journal of Neuro-Oncology</i> , <b>2020</b> , 146, 1714-180	4.8	9
278	Toxicity after adjuvant therapy for stage III uterine cancer. <i>Gynecologic Oncology</i> , <b>2020</b> , 159, 737-743	4.9	0
277	Using machine learning to create prognostic systems for endometrial cancer. <i>Gynecologic Oncology</i> , <b>2020</b> , 159, 744-750	4.9	6
276	Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 3325-3348	2.2	168
275	Economic Evaluations in National Cancer Institute-Sponsored Network Cancer Clinical Trials. <i>Value in Health</i> , <b>2020</b> , 23, 1653-1661	3.3	2
274	Coronavirus Spectrum Infections (COVID-19, MERS, SARS) in Cancer Patients: A Systematic Review of the Literature. <i>Cancer Investigation</i> , <b>2020</b> , 38, 436-444	2.1	3
273	Representativeness of Black Patients in Cancer Clinical Trials Sponsored by the National Cancer Institute Compared With Pharmaceutical Companies. <i>JNCI Cancer Spectrum</i> , <b>2020</b> , 4, pkaa034	4.6	24
272	Effect of regionalization of endometrial cancer care on site of care and patient travel. <i>American Journal of Obstetrics and Gynecology</i> , <b>2020</b> , 222, 58.e1-58.e10	6.4	4
271	Phase 1 Study of Erlotinib and Metformin in Metastatic Triple-Negative Breast Cancer. <i>Clinical Breast Cancer</i> , <b>2020</b> , 20, 80-86	3	9
270	Healthcare utilization and cost of care in elderly breast cancer patients enrolled in SWOG clinical trials. <i>Breast Cancer Research and Treatment</i> , <b>2020</b> , 181, 455-463	4.4	3

269	Investigator Use of Social Media for Recruitment of Patients for Cancer Clinical Trials. <i>JAMA Network Open</i> , <b>2020</b> , 3, e2031202	10.4	3
268	A comparison of nurses' and physicians' perception of cancer treatment burden based on reported adverse events. <i>Health and Quality of Life Outcomes</i> , <b>2019</b> , 17, 146	3	1
267	Neuroendocrine carcinoma of the endometrium: Disease course, treatment, and outcomes. <i>Gynecologic Oncology</i> , <b>2019</b> , 155, 254-261	4.9	7
266	Quality of Care and Outcomes of Patients With Gynecologic Malignancies Treated at Safety-Net Hospitals. <i>JNCI Cancer Spectrum</i> , <b>2019</b> , 3, pkz039	4.6	5
265	Dynamic Vascular Optical Tomographic Imaging for Peripheral Artery Disease and Breast Cancer <b>2019</b> , 353-400		0
264	Regionalization of care for women with ovarian cancer. <i>Gynecologic Oncology</i> , <b>2019</b> , 154, 394-400	4.9	5
263	Randomized Double-Blind Placebo-Controlled Biomarker Modulation Study of Vitamin D Supplementation in Premenopausal Women at High Risk for Breast Cancer (SWOG S0812). <i>Cancer Prevention Research</i> , <b>2019</b> , 12, 481-490	3.2	8
262	FOLFOX and FOLFIRI Use in Stage IV Colon Cancer: Analysis of SEER-Medicare Data. <i>Clinical Colorectal Cancer</i> , <b>2019</b> , 18, 133-140	3.8	19
261	Association between body mass index and response to duloxetine for aromatase inhibitor-associated musculoskeletal symptoms in SWOG S1202. <i>Cancer</i> , <b>2019</b> , 125, 2123-2129	6.4	10
260	Development and validation of a risk-calculator for adverse perioperative outcomes for women with ovarian cancer. <i>American Journal of Obstetrics and Gynecology</i> , <b>2019</b> , 220, 571.e1-571.e8	6.4	16
259	Clinical Usefulness of Bright White Light Therapy for Depressive Symptoms in Cancer Survivors: Results from a Series of Personalized (N-of-1) Trials. <i>Healthcare (Switzerland)</i> , <b>2019</b> , 8,	3.4	3
258	Sequencing of therapy in women with stage III endometrial carcinoma receiving adjuvant combination chemotherapy and radiation. <i>Gynecologic Oncology</i> , <b>2019</b> , 155, 13-20	4.9	5
257	Factors Associated with Multidisciplinary Consultations in Patients with Early Stage Breast Cancer. <i>Cancer Investigation</i> , <b>2019</b> , 37, 233-241	2.1	3
256	Use of fertility preservation services in female reproductive-aged cancer patients. <i>American Journal of Obstetrics and Gynecology</i> , <b>2019</b> , 221, 328.e1-328.e16	6.4	10
255	Safety of same-day discharge for minimally invasive hysterectomy for endometrial cancer. <i>American Journal of Obstetrics and Gynecology</i> , <b>2019</b> , 221, 239.e1-239.e11	6.4	5
254	Osteoporosis in colorectal cancer survivors: analysis of the linkage between SWOG trial enrollees and Medicare claims. <i>Archives of Osteoporosis</i> , <b>2019</b> , 14, 83	2.9	2
253	Use of Bevacizumab for Elderly Patients With Stage IV Colon Cancer: Analysis of SEER-Medicare Data. <i>Clinical Colorectal Cancer</i> , <b>2019</b> , 18, e294-e299	3.8	5
252	Osteonecrosis of the jaw in patients with cancer receiving zoledronic acid for bone metastases: SWOG S0702, NCT00874211.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 11502-11502	2.2	2



251	Sex differences in adverse event reporting in SWOG chemotherapy, biologic/immunotherapy, and targeted agent cancer clinical trials.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 11588-11588	2.2	4
250	The effect of metformin on sex hormones in non-diabetic breast cancer patients in CCTG MA.32: A Phase III randomized adjuvant trial of metformin versus placebo in addition to standard therapy.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 529-529	2.2	3
249	Randomized trial of text messaging (TM) to reduce early discontinuation of aromatase inhibitor (AI) therapy in women with breast cancer: SWOG S1105.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 6516-6516	2.2	4
248	Delay in receipt of newly prescribed oral anticancer drugs.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 6541-6541	2.2	3
247	Design and accrual of S1417CD: Development of a prospective financial impact assessment tool in patients with metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, TPS6652-TPS6652	2.2	1
246	Use of nonclinical staff to coordinate oral anticancer drug prescriptions.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 72-72	2.2	1
245	Diffuse optical tomography of the breast: a potential modifiable biomarker of breast cancer risk with neoadjuvant chemotherapy. <i>Biomedical Optics Express</i> , <b>2019</b> , 10, 4305-4315	3.5	4
244	Hypertension and use of bevacizumab among patients treated in community settings.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, e18279-e18279	2.2	
243	The impact of NCI-sponsored network group clinical trials on guideline care and new drug indications.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 6604-6604	2.2	
242	Factors associated with over and underuse of response evaluation in elderly myeloma patients.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, e19518-e19518	2.2	
241	A randomized trial of a healthy lifestyle intervention versus usual care on chemotherapy and endocrine therapy adherence rate in women with breast cancer: The Lifestyle Exercise and Nutrition Early After Diagnosis (LEANER) Study.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, TPS11633-TPS11633	2.2	1
240	Socioeconomic deprivation and cancer outcomes in patients treated in clinical trials.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 162-162	2.2	1
239	Patients enrolled in clinical trials with Medicaid or no insurance and overall survival benefits from new interventions.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 119-119	2.2	
238	Adherence to clinical practice guidelines for the prevention of acute chemotherapy-induced nausea and vomiting in children, adolescents, and young adults with cancer receiving their first cycle of highly emetogenic chemotherapy.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 19-19	2.2	
237	Comparison of attitudes and beliefs about cancer clinical trial enrollment between physicians, research staff, and cancer patients.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 170-170	2.2	
236	A standardized workflow to improve the consent process among patients initiating an oral anticancer drug.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 259-259	2.2	
235	Systematic Review and Meta-Analysis of the Magnitude of Structural, Clinical, and Physician and Patient Barriers to Cancer Clinical Trial Participation. <i>Journal of the National Cancer Institute</i> , <b>2019</b> , 111, 245-255	9.7	138
234	Association of National Cancer Institute-Sponsored Clinical Trial Network Group Studies With Guideline Care and New Drug Indications. <i>JAMA Network Open</i> , <b>2019</b> , 2, e1910593	10.4	12

233	Use and Misuse of Opioids After Gynecologic Surgical Procedures. <i>Obstetrics and Gynecology</i> , <b>2019</b> , 134, 250-260	4.9	24
232	Utility of preoperative breast MRI in patient selection for accelerated partial breast irradiation by different consensus guidelines. <i>Breast Journal</i> , <b>2019</b> , 25, 160-162	1.2	1
231	Obesity-associated Breast Inflammation among Hispanic/Latina Breast Cancer Patients. <i>Cancer Prevention Research</i> , <b>2019</b> , 12, 21-30	3.2	8
230	Prevalence of Hepatitis B Virus, Hepatitis C Virus, and HIV Infection Among Patients With Newly Diagnosed Cancer From Academic and Community Oncology Practices. <i>JAMA Oncology</i> , <b>2019</b> , 5, 497-505 <sup>13.4</sup>	13.4	34
229	Association of Patient Comorbid Conditions With Cancer Clinical Trial Participation. <i>JAMA Oncology</i> , <b>2019</b> , 5, 326-333	13.4	63
228	A randomized trial of interpersonal psychotherapy, problem solving therapy, and supportive therapy for major depressive disorder in women with breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2019</b> , 173, 353-364	4.4	12
227	Personal and clinical social support and adherence to adjuvant endocrine therapy among hormone receptor-positive breast cancer patients in an integrated health care system. <i>Breast Cancer Research and Treatment</i> , <b>2018</b> , 170, 623-631	4.4	17
226	Dynamic Diffuse Optical Tomography for Monitoring Neoadjuvant Chemotherapy in Patients with Breast Cancer. <i>Radiology</i> , <b>2018</b> , 287, 778-786	20.5	23
225	Survival by Hispanic ethnicity among patients with cancer participating in SWOG clinical trials. <i>Cancer</i> , <b>2018</b> , 124, 1760-1769	6.4	7
224	Two-Year Trends of Taxane-Induced Neuropathy in Women Enrolled in a Randomized Trial of Acetyl-L-Carnitine (SWOG S0715). <i>Journal of the National Cancer Institute</i> , <b>2018</b> , 110, 669-676	9.7	35
223	Racial disparities in young women with endometrial cancer. <i>Gynecologic Oncology</i> , <b>2018</b> , 148, 527-534	4.9	16
222	Trends in Sentinel Lymph Node Mapping and Adjuvant Therapy in Endometrial Carcinoma. <i>Cancer Investigation</i> , <b>2018</b> , 36, 190-198	2.1	9
221	Impact of hospital volume on racial disparities and outcomes for endometrial cancer. <i>Gynecologic Oncology</i> , <b>2018</b> , 149, 329-336	4.9	8
220	Identifying modifiable and non-modifiable risk factors associated with prolonged length of stay after hysterectomy for uterine cancer. <i>Gynecologic Oncology</i> , <b>2018</b> , 149, 545-553	4.9	2
219	Using Medicare Claims to Examine Long-term Prostate Cancer Risk of Finasteride in the Prostate Cancer Prevention Trial. <i>Journal of the National Cancer Institute</i> , <b>2018</b> , 110, 1208-1215	9.7	12
218	The scientific impact and value of large, NCI-sponsored randomized phase III cancer chemoprevention trials. <i>Cancer Epidemiology</i> , <b>2018</b> , 55, 117-122	2.8	3
217	Effect of Acupuncture vs Sham Acupuncture or Waitlist Control on Joint Pain Related to Aromatase Inhibitors Among Women With Early-Stage Breast Cancer: A Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2018</b> , 320, 167-176	27.4	136
216	Geographic Distribution and Survival Outcomes for Rural Patients With Cancer Treated in Clinical Trials. <i>JAMA Network Open</i> , <b>2018</b> , 1, e181235	10.4	57

215	A New Framework for Patient Engagement in Cancer Clinical Trials Cooperative Group Studies. <i>Journal of the National Cancer Institute</i> , <b>2018</b> , 110, 553-559	9.7	20
214	Utilization of ovarian transposition for fertility preservation among young women with pelvic malignancies who undergo radiotherapy. <i>American Journal of Obstetrics and Gynecology</i> , <b>2018</b> , 219, 415-417	6.4	6
213	Phase IB trial of ACY-1215 (Ricolinostat) combined with nab-paclitaxel in metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 1058-1058	2.2	1
212	CA15-3/MUC1 in CCTG MA-32 (NCT01101438): A phase III RCT of the effect of metformin vs. placebo on invasive disease free and overall survival in early stage breast cancer (BC).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 557-557	2.2	1
211	Geographic distribution and survival outcomes for rural cancer patients treated in clinical trials.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 6569-6569	2.2	2
210	Factors associated with non-adherence to lenalidomide in patients with multiple myeloma.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, e20031-e20031	2.2	2
209	The Breast Cancer Weight Loss (BWEL) trial: Randomized phase III trial evaluating the role of weight loss in adjuvant treatment of overweight and obese women with early-stage breast cancer (Alliance A011401).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, TPS598-TPS598	2.2	1
208	Patient comorbid conditions and cancer clinical trial participation.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 6540-6540	2.2	0
207	Omega-3 fatty acid use for obese breast cancer patients with aromatase inhibitor-related arthralgia (SWOG S0927).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 10000-10000	2.2	
206	Prevalence of HIV, hepatitis B virus (HBV), and hepatitis C virus (HCV) among newly diagnosed cancer patients treated in academic and community oncology practices: SWOG S1204.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 6600-6600	2.2	
205	Factors associated with follow-up physician visits among women with early stage breast cancer.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 6531-6531	2.2	
204	Impact of clinic characteristics on the adoption of a guideline-based standing order algorithm and patient accrual in the pragmatic cluster-randomized trial SWOG S1415CD (NCT02728596).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 60-60	2.2	
203	From A to Xeloda: Practical considerations for implementing a chemotherapy regimen ordering system intervention.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 57-57	2.2	
202	The influence of patient engagement on the design and implementation of a clinical trial to improve cancer care delivery.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 223-223	2.2	
201	Implementing an EHR guidelineBased intervention in paper ordering systems.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 56-56	2.2	
200	Adherence to treatment recommendations and outcomes for women with ovarian cancer at first recurrence. <i>Gynecologic Oncology</i> , <b>2018</b> , 148, 19-27	4.9	10
199	Association Between Hospital Financial Distress and Immediate Breast Reconstruction Surgery After Mastectomy Among Women With Ductal Carcinoma In Situ. <i>JAMA Surgery</i> , <b>2018</b> , 153, 344-351	5.4	5
198	Estimating global treatment toxicity burden from adverse-event data. <i>Cancer</i> , <b>2018</b> , 124, 858-864	6.4	5

197	Failure to Rescue and Mortality Following Resection of Intracranial Neoplasms. <i>Neurosurgery</i> , <b>2018</b> , 83, 263-269	3.2	6
196	National Cancer Institute Breast Cancer Steering Committee Working Group Report on Meaningful and Appropriate End Points for Clinical Trials in Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 3259-3268	2.2	10
195	Association of Cardiovascular Risk Factors With Cardiac Events and Survival Outcomes Among Patients With Breast Cancer Enrolled in SWOG Clinical Trials. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 2710-2717	2.2	40
194	Integrative Therapies During and After Breast Cancer Treatment: ASCO Endorsement of the SIO Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 2647-2655	2.2	145
193	Extent of Exclusions for Chronic Conditions in Breast Cancer Trials. <i>JNCI Cancer Spectrum</i> , <b>2018</b> , 2, pky0596	2.6	4
192	Acupuncture for Aromatase Inhibitor-Related Joint Pain Among Breast Cancer Patients. <i>JAMA - Journal of the American Medical Association</i> , <b>2018</b> , 320, 2270-2271	27.4	6
191	Phase II Feasibility Study of a Weight Loss Intervention in Female Breast and Colorectal Cancer Survivors (SWOG S1008). <i>Obesity</i> , <b>2018</b> , 26, 1539-1549	8	3
190	Use and outcomes of minimally invasive hysterectomy for women with nonendometrioid endometrial cancers. <i>American Journal of Obstetrics and Gynecology</i> , <b>2018</b> , 219, 463.e1-463.e12	6.4	7
189	Adherence to colonoscopy at 1 year following resection of localized colon cancer: a retrospective cohort study.. <i>Therapeutic Advances in Gastroenterology</i> , <b>2018</b> , 11, 1756284818765920	4.7	4
188	Omega-3 fatty acid use for obese breast cancer patients with aromatase inhibitor-related arthralgia (SWOG S0927). <i>Breast Cancer Research and Treatment</i> , <b>2018</b> , 172, 603-610	4.4	25
187	Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 326-332	2.2	50
186	Assessment of Electronic Alert to Reduce Overuse of Granulocyte Colony-Stimulating Factor in Patients Hospitalized for Febrile Neutropenia. <i>JAMA Oncology</i> , <b>2018</b> , 4, 996-998	13.4	1
185	Characteristics associated with prolonged length of stay after hysterectomy for benign gynecologic conditions. <i>American Journal of Obstetrics and Gynecology</i> , <b>2018</b> , 219, 89.e1-89.e15	6.4	10
184	Barriers to Recruitment and Adherence in a Randomized Controlled Diet and Exercise Weight Loss Intervention Among Minority Breast Cancer Survivors. <i>Journal of Immigrant and Minority Health</i> , <b>2017</b> , 19, 120-129	2.2	22
183	Utilization of sentinel lymph node biopsy for uterine cancer. <i>American Journal of Obstetrics and Gynecology</i> , <b>2017</b> , 216, 594.e1-594.e13	6.4	19
182	Disparities in the management of ectopic pregnancy. <i>American Journal of Obstetrics and Gynecology</i> , <b>2017</b> , 217, 49.e1-49.e10	6.4	23
181	Factors and Costs Associated With Delay in Treatment Initiation and Prolonged Length of Stay With Inpatient EPOCH Chemotherapy in Patients With Hematologic Malignancies. <i>Cancer Investigation</i> , <b>2017</b> , 35, 202-214	2.1	5
180	Diffuse optical tomography changes correlate with residual cancer burden after neoadjuvant chemotherapy in breast cancer patients. <i>Breast Cancer Research and Treatment</i> , <b>2017</b> , 162, 533-540	4.4	12

179	Patterns and reasons for switching classes of hormonal therapy among women with early-stage breast cancer. <i>Cancer Causes and Control</i> , <b>2017</b> , 28, 557-562	2.8	18
178	Effects of metformin versus placebo on vitamin B12 metabolism in non-diabetic breast cancer patients in CCTG MA.32. <i>Breast Cancer Research and Treatment</i> , <b>2017</b> , 164, 371-378	4.4	8
177	How do we increase uptake of tamoxifen and other anti-estrogens for breast cancer prevention?. <i>Npj Breast Cancer</i> , <b>2017</b> , 3, 20	7.8	27
176	Utility of radiation therapy for early-stage uterine papillary serous carcinoma. <i>Gynecologic Oncology</i> , <b>2017</b> , 145, 269-276	4.9	18
175	Utilization of gynecologic services in women with breast cancer receiving hormonal therapy. <i>American Journal of Obstetrics and Gynecology</i> , <b>2017</b> , 217, 59.e1-59.e12	6.4	7
174	Association between Body Mass Index and Cancer Survival in a Pooled Analysis of 22 Clinical Trials. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2017</b> , 26, 21-29	4	72
173	Understanding Breast Cancer Knowledge and Barriers to Treatment Adherence: A Qualitative Study Among Breast Cancer Survivors. <i>BioResearch Open Access</i> , <b>2017</b> , 6, 159-168	2.4	4
172	History of Diabetes and Survival Outcome Among Participants 65 Years or Older in SWOG Clinical Trials. <i>JCO Clinical Cancer Informatics</i> , <b>2017</b> , 1, 1-12	5.2	1
171	Randomized phase III trial evaluating the role of weight loss in adjuvant treatment of overweight and obese women with early breast cancer (Alliance A011401): study design. <i>Npj Breast Cancer</i> , <b>2017</b> , 3, 37	7.8	54
170	All-cause mortality in young women with endometrial cancer receiving progesterone therapy. <i>American Journal of Obstetrics and Gynecology</i> , <b>2017</b> , 217, 669.e1-669.e13	6.4	21
169	Trends in end-of-life care and health care spending in women with uterine cancer. <i>American Journal of Obstetrics and Gynecology</i> , <b>2017</b> , 217, 434.e1-434.e10	6.4	12
168	Association between survival time with metastatic breast cancer and aggressive end-of-life care. <i>Breast Cancer Research and Treatment</i> , <b>2017</b> , 166, 549-558	4.4	15
167	Using Delayed Toxicities to Re-evaluate Tolerability in Phase 2 Trials: A Case Example using Bortezomib. <i>Cancer Investigation</i> , <b>2017</b> , 35, 484-489	2.1	2
166	A stakeholder-informed randomized, controlled comparative effectiveness study of an order prescribing intervention to improve colony stimulating factor use for cancer patients receiving myelosuppressive chemotherapy: the TrACER study. <i>Journal of Comparative Effectiveness Research</i> , <b>2017</b> , 6, 461-470	2.1	7
165	BMI, Lifestyle Factors and Taxane-Induced Neuropathy in Breast Cancer Patients: The Pathways Study. <i>Journal of the National Cancer Institute</i> , <b>2017</b> , 109,	9.7	63
164	Comparative Effectiveness of Cancer Control and Survival after Robot-Assisted versus Open Radical Prostatectomy. <i>Journal of Urology</i> , <b>2017</b> , 197, 115-121	2.5	36
163	American Society of Clinical Oncology Summit on Addressing Obesity Through Multidisciplinary Provider Collaboration: Key Findings and Recommendations for Action. <i>Obesity</i> , <b>2017</b> , 25 Suppl 2, S34-S39	8	6
162	A randomized phase II trial of fulvestrant with or without ribociclib after progression on aromatase inhibition plus cyclin-dependent kinase 4/6 inhibition in patients with unresectable or metastatic hormone receptor positive, HER2 negative breast cancer.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, TPS1112-TPS1112	2.2	2

161	Social support at diagnosis and noninitiation, discontinuation, and nonadherence to adjuvant hormonal therapy in the Pathways Study.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 7-7	2.2	1
160	Factors associated with neurokinin-1 receptor antagonist use among commercially insured cancer patients receiving highly emetogenic chemotherapy.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 24-24	2.2	
159	Complementary and alternative medicine use and hormonal therapy initiation in women with hormone receptor-positive breast cancer: The BQUAL study.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, e13097-e13097	2.2	
158	NCI Breast Cancer Steering Committee Working Group (WG) report on meaningful and appropriate endpoints for clinical trials (CT) in metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 1073-1073	2.2	
157	Patterns of osteoporosis (OP) in survivors of colorectal cancer (CRC) enrolled on SWOG trials.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 10056-10056	2.2	
156	The scientific impact and value of large, NCI-sponsored randomized phase III cancer prevention trials.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 1541-1541	2.2	
155	Differences in global toxicity burden among patients and care providers during initial chemotherapy for breast cancer.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, e21649-e21649	2.2	
154	Two-year trends of taxane-induced neuropathy in women enrolled in a randomized trial of acetyl-L-carnitine (SWOG S0715).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 10093-10093	2.2	
153	Trends in Use and Outcomes of Women Undergoing Hysterectomy With Electric Power Morcellation. <i>JAMA - Journal of the American Medical Association</i> , <b>2016</b> , 316, 877-8	27.4	34
152	Long-term Diet and Biomarker Changes after a Short-term Intervention among Hispanic Breast Cancer Survivors: The ¡Cocinar Para Su Salud! Randomized Controlled Trial. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2016</b> , 25, 1491-1502	4	24
151	Predictors of Interventional Treatment Use for Venous Thromboembolism in Cancer Patients. <i>Cancer Investigation</i> , <b>2016</b> , 34, 408-14	2.1	1
150	Comorbidities and Risk of Chemotherapy-Induced Peripheral Neuropathy Among Participants 65 Years or Older in Southwest Oncology Group Clinical Trials. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 3014-22 <sup>2</sup>	2.2	122
149	Nonadherence to Medications for Chronic Conditions and Nonadherence to Adjuvant Hormonal Therapy in Women With Breast Cancer. <i>JAMA Oncology</i> , <b>2016</b> , 2, 1326-1332	13.4	42
148	A prospective cohort study of early discontinuation of adjuvant chemotherapy in women with breast cancer: the breast cancer quality of care study (BQUAL). <i>Breast Cancer Research and Treatment</i> , <b>2016</b> , 158, 127-138	4.4	12
147	Magnitude of risk for nodal metastasis associated with lymphovascular space invasion for endometrial cancer. <i>Gynecologic Oncology</i> , <b>2016</b> , 140, 387-93	4.9	29
146	Radiation Duration in Women with Cervical Cancer Treated with Primary Chemoradiation: A Population-Based Analysis. <i>Cancer Investigation</i> , <b>2016</b> , 34, 137-47	2.1	12
145	Natural history and outcome of neuroendocrine carcinoma of the cervix. <i>Gynecologic Oncology</i> , <b>2016</b> , 141, 247-254	4.9	44
144	Effect of Regional Hospital Competition and Hospital Financial Status on the Use of Robotic-Assisted Surgery. <i>JAMA Surgery</i> , <b>2016</b> , 151, 612-20	5.4	62

143	Comparative Effectiveness of Minimally Invasive Hysterectomy for Endometrial Cancer. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 1087-96	2.2	64
142	Underuse of BRCA testing in patients with breast and ovarian cancer. <i>American Journal of Obstetrics and Gynecology</i> , <b>2016</b> , 214, 761-3	6.4	27
141	Overuse of external beam radiotherapy for stage I endometrial cancer. <i>American Journal of Obstetrics and Gynecology</i> , <b>2016</b> , 215, 75.e1-7	6.4	4
140	Adverse Health Events Following Intermittent and Continuous Androgen Deprivation in Patients With Metastatic Prostate Cancer. <i>JAMA Oncology</i> , <b>2016</b> , 2, 453-61	13.4	64
139	National Cancer Institute-supported chemotherapy-induced peripheral neuropathy trials: outcomes and lessons. <i>Supportive Care in Cancer</i> , <b>2016</b> , 24, 1439-47	3.9	69
138	Body mass index, lifestyle factors, and taxane-induced neuropathy in women with breast cancer: The Pathways study.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 10002-10002	2.2	1
137	Understanding efficiency of chemotherapy delivery for planned chemotherapy admission at Columbia University Medical Center.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 206-206	2.2	
136	Impact of weight loss and exercise on VEGF levels in breast cancer survivors.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 10103-10103	2.2	0
135	Diffusion of abiraterone use in prostate cancer patients.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, e18062-e18062		
134	Comorbidities and risk of chemotherapy-induced peripheral neuropathy among participants in SWOG clinical trials.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 10001-10001	2.2	
133	Comparison of physicians, nurses' and patients' assessment of overall symptom burden.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, e18123-e18123	2.2	
132	Randomized trial of medroxyprogesterone acetate for prevention of endometrial pathology from adjuvant tamoxifen for breast cancer: SWOG S9630.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 547-547	2.2	
131	Axillary evaluation and lymphedema in women with ductal carcinoma in situ. <i>Breast Cancer Research and Treatment</i> , <b>2016</b> , 158, 373-84	4.4	13
130	Reply to F. Dayyani et al. <i>Journal of Oncology Practice</i> , <b>2016</b> , 12, 277	3.1	
129	Abdominal vs Minimally Invasive Hysterectomy-Reply. <i>JAMA - Journal of the American Medical Association</i> , <b>2016</b> , 316, 2677-2678	27.4	
128	Nonadherence to Oral Medications for Chronic Conditions in Breast Cancer Survivors. <i>Journal of Oncology Practice</i> , <b>2016</b> , 12, e800-9	3.1	20
127	Complementary and alternative medicine use among US cancer survivors. <i>Journal of Cancer Survivorship</i> , <b>2016</b> , 10, 850-64	5.1	54
126	Randomized sham-controlled pilot trial of weekly electro-acupuncture for the prevention of taxane-induced peripheral neuropathy in women with early stage breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2016</b> , 156, 453-464	4.4	55

125	Association Between Geographic Access to Cancer Care and Receipt of Radiation Therapy for Rectal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2016</b> , 94, 719-28	4	46
124	Use and Costs of Disease Monitoring in Women With Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 2820-6	2.2	22
123	Safety, Utilization, and Cost of Image-Guided Percutaneous Liver Biopsy Among Cancer Patients. <i>Cancer Investigation</i> , <b>2016</b> , 34, 189-96	2.1	8
122	Psychosocial factors related to non-persistence with adjuvant endocrine therapy among women with breast cancer: the Breast Cancer Quality of Care Study (BQUAL). <i>Breast Cancer Research and Treatment</i> , <b>2016</b> , 157, 133-43	4.4	38
121	Prescription of extended-duration thromboprophylaxis after high-risk, abdominopelvic cancer surgery. <i>Gynecologic Oncology</i> , <b>2016</b> , 141, 531-537	4.9	15
120	Survivorship care plans and adherence to lifestyle recommendations among breast cancer survivors. <i>Journal of Cancer Survivorship</i> , <b>2016</b> , 10, 956-963	5.1	29
119	Association Between Complementary and Alternative Medicine Use and Breast Cancer Chemotherapy Initiation: The Breast Cancer Quality of Care (BQUAL) Study. <i>JAMA Oncology</i> , <b>2016</b> , 2, 1170-6	13.4	42
118	Reply. <i>American Journal of Obstetrics and Gynecology</i> , <b>2016</b> , 215, 134-5	6.4	
117	Trends in use and safety of image-guided transthoracic needle biopsies in patients with cancer. <i>Journal of Oncology Practice</i> , <b>2015</b> , 11, e351-9	3.1	21
116	The Influence of Hospital and Surgeon Factors on the Prevalence of Axillary Lymph Node Evaluation in Ductal Carcinoma In Situ. <i>JAMA Oncology</i> , <b>2015</b> , 1, 323-32	13.4	20
115	Relationship between surgical oncologic outcomes and publically reported hospital quality and satisfaction measures. <i>Journal of the National Cancer Institute</i> , <b>2015</b> , 107,	9.7	12
114	Food environments are relevant to recruitment and adherence in dietary modification trials. <i>Nutrition Research</i> , <b>2015</b> , 35, 480-8	4	7
113	Household net worth, racial disparities, and hormonal therapy adherence among women with early-stage breast cancer. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 1053-9	2.2	82
112	Quality of Care, Including Survivorship Care Plans. <i>Advances in Experimental Medicine and Biology</i> , <b>2015</b> , 862, 255-69	3.6	5
111	Long-term mortality among women with epithelial ovarian cancer. <i>Gynecologic Oncology</i> , <b>2015</b> , 138, 421-429	4.9	44
110	Methods to Standardize a Multicenter Acupuncture Trial Protocol to Reduce Aromatase Inhibitor-related Joint Symptoms in Breast Cancer Patients. <i>JAMS Journal of Acupuncture and Meridian Studies</i> , <b>2015</b> , 8, 152-8	1.2	8
109	Use and duration of chemotherapy and its impact on survival in early-stage ovarian cancer. <i>Gynecologic Oncology</i> , <b>2015</b> , 137, 203-9	4.9	14
108	Barriers and facilitators to recruitment to a culturally-based dietary intervention among urban Hispanic breast cancer survivors. <i>Journal of Racial and Ethnic Health Disparities</i> , <b>2015</b> , 2, 244-55	3.5	14



107	Association Between Geographic Access to Cancer Care, Insurance, and Receipt of Chemotherapy: Geographic Distribution of Oncologists and Travel Distance. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 3177-85	2.2	116
106	Population-level trends in relative survival for cervical cancer. <i>American Journal of Obstetrics and Gynecology</i> , <b>2015</b> , 213, 670.e1-7	6.4	31
105	Recommendations for Obesity Clinical Trials in Cancer Survivors: American Society of Clinical Oncology Statement. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 3961-7	2.2	44
104	Vitamin D-related gene polymorphisms, plasma 25-hydroxyvitamin D, and breast cancer risk. <i>Cancer Causes and Control</i> , <b>2015</b> , 26, 187-203	2.8	51
103	Randomized exercise trial of aromatase inhibitor-induced arthralgia in breast cancer survivors. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 1104-11	2.2	183
102	Breast Cancer Chemoprevention among High-risk Women and those with Ductal Carcinoma In Situ. <i>Breast Journal</i> , <b>2015</b> , 21, 377-86	1.2	27
101	Identifying Predictors of Taxane-Induced Peripheral Neuropathy Using Mass Spectrometry-Based Proteomics Technology. <i>PLoS ONE</i> , <b>2015</b> , 10, e0145816	3.7	22
100	Effect of metformin vs placebo on and metabolic factors in NCIC CTG MA.32. <i>Journal of the National Cancer Institute</i> , <b>2015</b> , 107,	9.7	88
99	Complications Following Stereotactic Needle Biopsy of Intracranial Tumors. <i>World Neurosurgery</i> , <b>2015</b> , 84, 1084-9	2.1	71
98	Risk stratification and outcomes of women undergoing surgery for ovarian cancer. <i>Gynecologic Oncology</i> , <b>2015</b> , 138, 62-9	4.9	30
97	Randomized Multicenter Placebo-Controlled Trial of Omega-3 Fatty Acids for the Control of Aromatase Inhibitor-Induced Musculoskeletal Pain: SWOG S0927. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 1910-7	2.2	65
96	Economic and Survival Implications of Use of Electric Power Morcellation for Hysterectomy for Presumed Benign Gynecologic Disease. <i>Journal of the National Cancer Institute</i> , <b>2015</b> , 107,	9.7	12
95	Use of Electric Power Morcellation and Prevalence of Underlying Cancer in Women Who Undergo Myomectomy. <i>JAMA Oncology</i> , <b>2015</b> , 1, 69-77	13.4	55
94	Reply to L. Gianni et al. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 4312	2.2	
93	Influence of treatment center and hospital volume on survival for locally advanced cervical cancer. <i>Gynecologic Oncology</i> , <b>2015</b> , 139, 506-12	4.9	35
92	High versus low-dose rate brachytherapy for cervical cancer. <i>Gynecologic Oncology</i> , <b>2015</b> , 136, 534-41	4.9	17
91	Dietary modifications, weight loss, and changes in metabolic markers affect global DNA methylation in Hispanic, African American, and Afro-Caribbean breast cancer survivors. <i>Journal of Nutrition</i> , <b>2015</b> , 145, 783-90	4.1	53
90	The diffusion of docetaxel in patients with metastatic prostate cancer. <i>Journal of the National Cancer Institute</i> , <b>2015</b> , 107,	9.7	12

89	Phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: SWOG/Alliance/ECOG-ACRIN/NCIC Clinical Trials Group/NRG Oncology study S0307.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 503-503	2.2	14
88	Phase II feasibility study of a physical activity and dietary change weight loss intervention in a subset analysis of breast cancer survivors (SWOG S1008).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 9572-9572	2.2	1
87	Symptom clusters in patients with advanced prostate cancer.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, e20647-e20647	2.2	1
86	Symptoms: Aromatase Inhibitor Induced Arthralgias. <i>Advances in Experimental Medicine and Biology</i> , <b>2015</b> , 862, 89-100	3.6	13
85	Identifying predictors of taxane-induced peripheral neuropathy using shotgun proteomics technology.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 9607-9607	2.2	
84	Long-term consequences of intermittent and continuous androgen deprivation in older patients with metastatic prostate cancer.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 5008-5008	2.2	
83	The influence of hospital and surgeon factors on the prevalence of axillary evaluation in ductal carcinoma in situ.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 6529-6529	2.2	
82	Serum tumor marker utilization in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 6599-6599	2.2	
81	Randomized sham controlled pilot trial of weekly electro-acupuncture for the prevention of taxane-induced peripheral neuropathy.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, e20738-e20738	2.2	
80	Association between geographic access to cancer care and receipt of chemotherapy: Geographic distribution of oncologists and travel distance.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, e17561-e17561	2.2	
79	Clinical practice guidelines on the use of integrative therapies as supportive care in patients treated for breast cancer. <i>Journal of the National Cancer Institute Monographs</i> , <b>2014</b> , 2014, 346-58	4.8	161
78	Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 1941-67	2.2	788
77	Presurgical trial of metformin in overweight and obese patients with newly diagnosed breast cancer. <i>Cancer Investigation</i> , <b>2014</b> , 32, 150-7	2.1	54
76	Erythropoiesis-stimulating agent use after changes in medicare reimbursement policies. <i>Journal of Oncology Practice</i> , <b>2014</b> , 10, 264-9	3.1	6
75	American Society of Clinical Oncology position statement on obesity and cancer. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 3568-74	2.2	322
74	The change from brand-name to generic aromatase inhibitors and hormone therapy adherence for early-stage breast cancer. <i>Journal of the National Cancer Institute</i> , <b>2014</b> , 106,	9.7	63
73	Uterine pathology in women undergoing minimally invasive hysterectomy using morcellation. <i>JAMA - Journal of the American Medical Association</i> , <b>2014</b> , 312, 1253-5	27.4	105
72	Comparison of survival outcomes among cancer patients treated in and out of clinical trials. <i>Journal of the National Cancer Institute</i> , <b>2014</b> , 106, dju002	9.7	137

71	Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial. <i>Lancet Oncology, The</i> , <b>2014</b> , 15, 474-82	21.7	38
70	Safety and tolerance of radical hysterectomy for cervical cancer in the elderly. <i>Gynecologic Oncology</i> , <b>2014</b> , 134, 36-41	4.9	18
69	Presurgical evaluation of the AKT inhibitor MK-2206 in patients with operable invasive breast cancer.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 2613-2613	2.2	3
68	SWOG S0307 phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: Comparison of toxicities and patient-stated preference for oral versus intravenous delivery.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 558-558	2.2	11
67	Omega-3 fatty acids for aromatase inhibitor-induced musculoskeletal symptoms in women with early-stage breast cancer (SWOG S0927).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 9532-9532	2.2	2
66	A multicenter phase II study of docosahexaenoic acid (DHA) in patients (pts) with a history of breast cancer (BC), premalignant lesions, or benign breast disease.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, TPS1615-TPS1615	2.2	1
65	Bone health history in breast cancer patients on aromatase inhibitors. <i>PLoS ONE</i> , <b>2014</b> , 9, e111477	3.7	11
64	Vitamin B12 (Vit B12) biochemical (BCH) deficiency (DEF) in non-diabetic breast cancer (BC) patients on NCIC CTG MA.32: A phase III randomized adjuvant BC trial comparing metformin (Met) to placebo (Pl).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 542-542	2.2	
63	Correlation between risk benefit index and uptake of breast cancer chemoprevention.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 1568-1568	2.2	
62	Phase I/II trial of ruxolitinib in combination with trastuzumab in metastatic HER2-positive breast cancer.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, TPS666-TPS666	2.2	
61	Relationship between surgical oncologic outcomes and publically reported hospital quality measures.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 6504-6504	2.2	
60	Prolonged radiation duration in women with cervical cancer: A population-based analysis of associated factors and impact on survival.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 6518-6518	2.2	
59	Looking beyond the first cycle in phase I cancer clinical trials.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 6587-6587	2.2	
58	Phase II study of glucosamine with chondroitin on aromatase inhibitor-associated joint symptoms in women with breast cancer. <i>Supportive Care in Cancer</i> , <b>2013</b> , 21, 1077-87	3.9	38
57	Randomized controlled trial of a clinic-based survivorship intervention following adjuvant therapy in breast cancer survivors. <i>Breast Cancer Research and Treatment</i> , <b>2013</b> , 138, 795-806	4.4	87
56	Supplement use during an intergroup clinical trial for breast cancer (S0221). <i>Breast Cancer Research and Treatment</i> , <b>2013</b> , 137, 903-13	4.4	16
55	Disparities and challenges in adherence to oral antineoplastic agents. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2013</b> , 271-6	7.1	15
54	Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 2627-33	2.2	143

53	Contraindicated use of bevacizumab and toxicity in elderly patients with cancer. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 3592-9	2.2	43
52	Patient income level and cancer clinical trial participation. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 536-42	2.2	153
51	Optical biomarkers for breast cancer derived from dynamic diffuse optical tomography. <i>Journal of Biomedical Optics</i> , <b>2013</b> , 18, 096012	3.5	49
50	Effect of metformin versus placebo on weight and metabolic factors in initial patients enrolled onto NCIC CTG MA.32, a multicenter adjuvant randomized controlled trial in early-stage breast cancer (BC).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 1033-1033	2.2	2
49	Uptake and patterns of use of gemcitabine for stage IV pancreatic cancer.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, e15074-e15074	2.2	
48	Ethnic differences in tumor proliferation in women with early-stage breast cancer.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 560-560	2.2	
47	Dose-dependent pharmacokinetic (PK) interaction of pegylated liposomal doxorubicin (PLD) with escalating doses of veliparib in a phase I study.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 2591-2591	2.2	
46	Reply to S. Sukumar et al. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 2932-2933	2.2	
45	Uptake and economic impact of first-cycle colony-stimulating factor use during adjuvant treatment of breast cancer. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 806-12	2.2	25
44	Comparative effectiveness research in oncology methodology: observational data. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 4215-22	2.2	108
43	Use of a urine anastrozole assay to determine treatment discontinuation among women with hormone-sensitive breast cancer: a pilot study. <i>Journal of Oncology Practice</i> , <b>2012</b> , 8, e100-4	3.1	8
42	Mutational analysis of circulating tumor cells in breast cancer patients by targeted clonal sequencing.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 10516-10516	2.2	1
41	SWOG S0715: Randomized placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy during adjuvant breast cancer therapy.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 9018-9018	2.2	1
40	Aromatase inhibitors, arthralgias, and exercise in breast cancer survivors.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, TPS669-TPS669	2.2	2
39	Patterns of decision making about cancer clinical trial participation among the online cancer treatment community: A collaboration between SWOG and NexCura.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, CRA6009-CRA6009	2.2	1
38	Patterns of decision making about cancer clinical trial participation among the online cancer treatment community: A collaboration between SWOG and NexCura.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, CRA6009-CRA6009	2.2	
37	Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2011</b> , 126, 529-37	4.7	533
36	Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents. <i>Breast Cancer Research and Treatment</i> , <b>2011</b> , 126, 215-20	4.4	154

35	Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy. <i>Breast Cancer Research and Treatment</i> , <b>2011</b> , 125, 767-74	4.4	164
34	Association between prescription co-payment amount and compliance with adjuvant hormonal therapy in women with early-stage breast cancer. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 2534-42	2.2	232
33	Digital optical tomography system for dynamic breast imaging. <i>Journal of Biomedical Optics</i> , <b>2011</b> , 16, 076014	3.5	54
32	Prevention of bone loss by zoledronic acid in premenopausal women undergoing adjuvant chemotherapy persist up to one year following discontinuing treatment. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2010</b> , 95, 559-66	5.6	43
31	Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 4120-8	2.2	534
30	Randomized, blinded, sham-controlled trial of acupuncture for the management of aromatase inhibitor-associated joint symptoms in women with early-stage breast cancer. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 1154-60	2.2	206
29	Reply to S.A. Narod. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, e700-e700	2.2	
28	Changes in markers of ovarian reserve and endocrine function in young women with breast cancer undergoing adjuvant chemotherapy. <i>Cancer</i> , <b>2010</b> , 116, 2099-105	6.4	67
27	Patterns of use and risks associated with erythropoiesis-stimulating agents among Medicare patients with cancer. <i>Journal of the National Cancer Institute</i> , <b>2009</b> , 101, 1633-41	9.7	63
26	Reply to R.T. Chlebowski. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, e74-e74	2.2	
25	Influence of private practice setting and physician characteristics on the use of breast cancer adjuvant chemotherapy for elderly women. <i>Cancer</i> , <b>2009</b> , 115, 3848-57	6.4	28
24	Minority report—how best to analyze clinical trial data to address disparities. <i>Breast Cancer Research and Treatment</i> , <b>2009</b> , 118, 519-521	4.4	2
23	Ethnicity and persistent symptom burden in breast cancer survivors. <i>Journal of Cancer Survivorship</i> , <b>2009</b> , 3, 241-50	5.1	75
22	Management of complications from estrogen deprivation in breast cancer patients. <i>Current Oncology Reports</i> , <b>2009</b> , 11, 29-36	6.3	0
21	Impact of primary prophylaxis on febrile neutropenia within community practices in the US. <i>Journal of Medical Economics</i> , <b>2009</b> , 12, 203-10	2.4	18
20	Surgeon characteristics and use of breast conservation surgery in women with early stage breast cancer. <i>Annals of Surgery</i> , <b>2009</b> , 249, 828-33	7.8	57
19	Patients' Perceptions of Physician-Patient Discussions and Adverse Events with Cancer Therapy. <i>Archives of Drug Information</i> , <b>2008</b> , 1, 70-78		9
18	Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin's lymphoma. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 3159-65	2.2	284

17	Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 4739-45	2.2	129
16	Surgeon characteristics and receipt of adjuvant radiotherapy in women with breast cancer. <i>Journal of the National Cancer Institute</i> , <b>2008</b> , 100, 199-206	9.7	76
15	Pilot study of acupuncture for the treatment of joint symptoms related to adjuvant aromatase inhibitor therapy in postmenopausal breast cancer patients. <i>Journal of Cancer Survivorship</i> , <b>2007</b> , 1, 283-91	5.1	68
14	Racial disparities in treatment and survival of male breast cancer. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 1089-98	2.2	49
13	Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 3877-83	2.2	351
12	Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy. <i>Journal of the National Cancer Institute</i> , <b>2007</b> , 99, 196-205	9.7	226
11	Timing of adjuvant chemotherapy initiation after surgery for stage III colon cancer. <i>Cancer</i> , <b>2006</b> , 107, 2581-8	6.4	138
10	Delay in initiating adjuvant radiotherapy following breast conservation surgery and its impact on survival. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2006</b> , 65, 1353-60	4	133
9	Delay of adjuvant chemotherapy initiation following breast cancer surgery among elderly women. <i>Breast Cancer Research and Treatment</i> , <b>2006</b> , 99, 313-21	4.4	131
8	Treatment of hot flashes in breast and prostate cancer. <i>Expert Opinion on Pharmacotherapy</i> , <b>2005</b> , 6, 1095-106	4	30
7	Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 8597-605	2.2	260
6	Racial disparities in treatment and survival among women with early-stage breast cancer. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 6639-46	2.2	245
5	Patterns and outcomes of chemotherapy for elderly patients with stage II ovarian cancer: a population-based study. <i>Gynecologic Oncology</i> , <b>2004</b> , 92, 293-9	4.9	18
4	Effectiveness of platinum-based chemotherapy among elderly patients with advanced ovarian cancer. <i>Gynecologic Oncology</i> , <b>2004</b> , 94, 540-9	4.9	56
3	Prevention and management of osteoporosis in women with breast cancer and men with prostate cancer. <i>Current Oncology Reports</i> , <b>2004</b> , 6, 277-84	6.3	7
2	Ethnic neutropenia and treatment delay in African American women undergoing chemotherapy for early-stage breast cancer. <i>Journal of the National Cancer Institute</i> , <b>2003</b> , 95, 1545-8	9.7	104
1	Outcomes of tamoxifen chemoprevention for breast cancer in very high-risk women: a cost-effectiveness analysis. <i>Journal of Clinical Oncology</i> , <b>2002</b> , 20, 9-16	2.2	48